Recombinant human leukocyte interferon-α 2b stimulates the synthesis and release of a 90k tumor-associated antigen in human breast cancer cells

✍ Scribed by S. Iacobelli; G. Scambia; C. Natoli; P. Benedetti Panici; G. Baiocchi; L. Perrone; S. Mancuso

• Publisher: John Wiley and Sons
• Year: 1988
• Tongue: French
• Weight: 322 KB
• Volume: 42
• Category: Article
• ISSN: 0020-7136
• DOI: 10.1002/ijc.2910420207

✦ Synopsis

We have previously reported the production of a new monoclonal antibody (MAb) (SP-2) recognizing a 90-kDa tumorassociated antigen, termed 9OK. which is increased in the serum of many cancer patients. Treatment of CG5 human breast cancer cells with recombinant interferon-a 2b (rlFN-a 2b) can increase the synthesis and release, in culture medium, of the 90K. The effect of rlFN-a 2b was dose-related and occurred at concentrations which did not affect cell proliferation. The increase of 90K expression was due to de novo protein synthesis since cycloheximide, added within 3 hr of the beginning of rlFN-a Zb stimulation treatment, completely abolished the effect of rlFN-a 2b. The stimulatory effect of rlFN-a 2b was already evident after 24 hr treatment. Finally, an increase in serum 90K levels was observed in 3 patients with advanced breast cancer receiving a short course of rlFNa 2b (Intron A). No effect of rlFN-a 2b was seen in 3 normal women. The ability of rlFN-a 2b to increase the synthesis and release of 9OK both in vitro and in vivo may be of clinical importance in the early detection of tumors.